Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 9.27
- Piotroski Score 7.00
- Grade Buy
- Symbol (ROIV)
- Company Roivant Sciences Ltd.
- Price $11.54
- Changes Percentage (0.52%)
- Change $0.06
- Day Low $11.36
- Day High $11.56
- Year High $13.06
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/11/2024
- Fiscal Year End N/A
- Average Stock Price Target $15.00
- High Stock Price Target $20.00
- Low Stock Price Target $10.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $5.23
- Trailing P/E Ratio 2
- Forward P/E Ratio 2
- P/E Growth 2
- Net Income $4.35 B
Income Statement
Quarterly
Annual
Latest News of ROIV
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is Roivant Sciences Ltd. (ROIV) the Best Guru Stock To Buy Now?
A list of the 10 Best Guru Stocks includes Roivant Sciences Ltd. (NASDAQ:ROIV). Hedge funds focus on stock picking for profits. The GURU ETF combines Buffett's advice with hedge funds' top stocks. Roi...
By Yahoo! Finance | 6 days ago -
Organon to Buy Roivant's Dermavant Unit in Deal Worth Up to $1.2 Billion
Organon is acquiring Dermavant Sciences for up to $1.2 billion, expanding its dermatology portfolio with Vtama, a topical therapy for psoriasis. Organon will make an upfront payment of $175 million an...
By MarketWatch | 1 week ago -
Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer
Bayer received $14 million upfront for mosliciguat, a lung-targeted sGC activator. Pulmovant presented promising Phase 1b data at the ERS Congress. The drug showed significant reductions in pulmonary ...
By Yahoo! Finance | 2 weeks ago